Stockreport

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for Z [Read more]